- Conditions: Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Prostate Cancer
Sponsors: Astellas Scientific & Medical Affairs, Inc.; Medivation, Inc.
Recruiting - verified April 2016
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145 (duvelisib); Drug: Ofatumumab
Sponsor: Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2016